|Articles|May 31, 2007

Could Biopsy Port Valves be a Source for Potential Flexible Endoscope Contamination?

Newsletter

Stay prepared and protected with the Infection Control Today newsletter, delivering essential updates, best practices, and expert insights for infection prevention professionals.

Subscribe

Related Content

Copacabana Beach and Ipanema Beach in Rio de Janeiro, Brazil (Adobe Stock 193839900 by f11photo)

AIDS 2026: Closing the Last-Mile Gap: Bringing HIV Care From Malawi’s Clinics Into Children’s Homes

ByTori Whitacre Martonicz, MA

August 13th 2026

Bug of the Month: You Never See Me Coming

ByTori Whitacre Martonicz, MA

August 12th 2026

Person washing hands. (Adobe Stock 200575602 By kieferpix)

From “Gotcha” to Coaching: Using RTLS to Improve Hand Hygiene

ByTori Whitacre Martonicz, MA

August 11th 2026

AIDS 2026: Malawi Program Achieves 10-fold Reduction in HIV Positivity Among Exposed Infants

ByTori Whitacre Martonicz, MA

August 10th 2026

Paper with urinary tract infection written on it and pills. (Adobe Stock 82815499 by Vitalii Vodolazskyi)

Global $17 Million Trial to Evaluate Phage Therapy for Drug-Resistant Recurrent UTIs

ByInfection Control Today® Editorial Staff

August 10th 2026

Could Biopsy Port Valves be a Source for Potential Flexible Endoscope Contamination?

Related Content

AIDS 2026: Closing the Last-Mile Gap: Bringing HIV Care From Malawi’s Clinics Into Children’s Homes

Bug of the Month: You Never See Me Coming

From “Gotcha” to Coaching: Using RTLS to Improve Hand Hygiene

AIDS 2026: Malawi Program Achieves 10-fold Reduction in HIV Positivity Among Exposed Infants

Global $17 Million Trial to Evaluate Phage Therapy for Drug-Resistant Recurrent UTIs

Trending on Infection Control Today

Bug of the Month: You Never See Me Coming

From “Gotcha” to Coaching: Using RTLS to Improve Hand Hygiene

Global $17 Million Trial to Evaluate Phage Therapy for Drug-Resistant Recurrent UTIs

AIDS 2026: Closing the Last-Mile Gap: Bringing HIV Care From Malawi’s Clinics Into Children’s Homes

FDA Accepts Merck Application to Expand ENFLONSIA Protection Into Second RSV Season